MNMD - Mind Medicine (MindMed) Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
MNMD price evolution
MNMD
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $295.28 | $243.13 | $252.33 | $99.7 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $299.36 | $247.69 | $255.47 | $103.87 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $319.77 | $268.14 | $275.53 | $124.54 |
| Current liabilities | ||||
| Accounts payable | $2.15 | $2.94 | $7.59 | $4.14 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $33.27 | $41.85 | $65.27 | $32.25 |
| Long term debt | $24.31 | $24.25 | $14.19 | $0.03 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $57.58 | $66.1 | $79.47 | $46.41 |
| Shareholders' equity | ||||
| Retained earnings | -$364.14 | -$350.45 | -$344.6 | -$290.2 |
| Other shareholder equity | $0.82 | $0.83 | $0.84 | $0.34 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $99.7 | $142.14 | $133.54 | $80.09 |
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $103.87 | $146.06 | $137.22 | $81.52 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $124.54 | $169.99 | $164 | $81.52 |
| Current liabilities | ||||
| Accounts payable | $4.14 | $2.11 | $4.18 | $2.02 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $32.25 | $17.89 | $10.41 | $3.01 |
| Long term debt | $0.03 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $46.41 | $19.08 | $12.34 | $5.65 |
| Shareholders' equity | ||||
| Retained earnings | -$290.2 | -$194.47 | -$137.67 | -$44.64 |
| Other shareholder equity | $0.34 | $0.63 | $1.05 | $0.28 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $24.79 | $24.46 | $22.2 | $22.2 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $2.75 | $2.62 | $0.7 | $1.31 |
| Net income | ||||
| Net income | -$13.68 | -$5.85 | -$54.4 | -$23.86 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $93.87 | $66.33 | $93.85 | |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$1.16 | |||
| Interest expense | $4.82 | $1.69 | -$0.45 | |
| Net income | ||||
| Net income | -$95.73 | -$56.8 | -$93.04 | -$35.34 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $249.39 | $180.03 | $169.25 | $21.85 |
| Effect of exchange rate | -$0.03 | -$0.02 | -$0.02 | $0.08 |
| Change in cash and equivalents | $195.58 | $143.43 | $152.63 | -$42.44 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.3 | |||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $21.85 | $59.05 | $98.82 | |
| Effect of exchange rate | $0.08 | -$0.31 | $0.74 | |
| Change in cash and equivalents | -$42.44 | $8.6 | $53.44 | |
News
Fundamentals
| Market cap | $979.09M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 81.59M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$97.80M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -10.01 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 3.62 |
| EPS | -$1.20 |
|---|---|
| ROA | -39.60% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 9.00 |
| Quick ratio | N/A |